63
Participants
Start Date
July 6, 2020
Primary Completion Date
February 1, 2021
Study Completion Date
February 1, 2021
Zanubrutinib
320 mg (4 x 80 mg) capsules administered orally once daily
Supportive Care
Supportive care treatment was selected and administered as deemed appropriate by the study investigator
Placebo
Placebo to match zanubrutinib
Medstar Heath Research Institute Medstar Washington Hospital Center, Washington D.C.
John D Archbold Memorial Hospital, Thomasville
Medical College of Wisconsin, Milwaukee
Loyola University Medical Center, Maywood
Therapeutics Concepts, Houston
Joe Arrington Cancer Research and Treatment Center, Lubbock
St Jude Medical Center, Fullerton
Massachusetts General Hospital, Boston
The Brigham and Womens Hospital, Inc, Boston
Rutgers University Hospital, Newark
Lead Sponsor
BeiGene
INDUSTRY